Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide LAR in ADPKD with moderate to severe renal insufficiency
2011-000138-12Phase 3Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Dec 2011
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Octreotide LAR with Placebo (2 arms). Primary endpoints: Change in total kidney volume and Rate of glomerular filtration rate decline. Started Dec 2011; status: completed.
02
Drugs
octreotide
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2011-000138-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000138-12.